It is well reported that levels of C-Alb or HCit differ significantly between individuals who experience meaningful clinical outcomes and those who do not (e.g., mortality, CKD progression, cardiovascular events, even anemia and erythropoietin resistance) [1]. The gene discussed is ALB; the disease is anemia.